Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.62 |
| ▸ | GHSR | Q92847 | 2/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.59 |
| ▸ | ITGAL | P20701 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181464 | 1.00 | ECE1 (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30052260 | 0.96 | GHSR (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL31606505 | 0.94 | GHSR (0.65) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL29533411 | 0.93 | GHSR (0.65) | ECE1GHSRITGB2ICAM1ITGAL | |
| SCHEMBL29657708 | 0.92 | ERAP2 (0.62) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30223334 | 0.92 | GHSR (0.57) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30834217 | 0.92 | ECE1 (0.56) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL30736101 | 0.91 | MMP2 (0.60) | ECE1GHSR | |
| SCHEMBL21641802 | 0.91 | ITGB2 (0.67) | ECE1GHSRERAP2ITGB2ICAM1 | |
| SCHEMBL21641801 | 0.91 | ITGB2 (0.67) | ECE1GHSRERAP2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023247999-A1 | PEPTIDIC PAIN MODULATORS AND METHODS FOR PRODUCING AND USING THE SAME | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2023-12-28 | — | — | WO | claimed |
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | claimed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-119930753-A | Milk casein hydrolysate with anti-inflammatory effect, and preparation method and application thereof | 澳优乳业（中国）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118894917-B | Feta protein zymolyte, preparation method and application | 澳优乳业（中国）有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2023247999-A1 | PEPTIDIC PAIN MODULATORS AND METHODS FOR PRODUCING AND USING THE SAME | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2023-12-28 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | disclosed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | disclosed |
| EP-0204374-A2 | Tripeptidic compounds having hypotensive activity | POLIFARMA S.p.A. (IT) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ECE1 1629/4885GHSR 429/4885ERAP2 831/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ECE1 997/4885GHSR 679/4885ERAP2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.